Introduction angiogenesis, and virtually no companies interested in developing anti-angiogenic drugs. What has changed this situation so Roughly a decade before the inaugural issue of Carcinogenesis dramatically such that there are now over 20 anti-angiogenic was published, Dr Judah Folkman articulated several hypodrugs being tested in various phase clinical trials, as shown theses regarding what he felt was the critical importance of in Table I (9-12), and numerous others in preclinical tumor angiogenesis in the development and metastatic spread development? of tumors, and how therapeutic inhibition of such angiogenesis might be exploited as a new and novel means of treating cancer (1, 2) . His ideas were based not only on his own work, Past and present but also on some studies of a small number of insightful What follows are 10 of the most significant reasons (with no investigators such as Algire and Chalkley (3), Greenblatt and particular significance attached to their order) for the explosive Shubik (4) and Warren (5) . Indeed, it was Shubik who first growth in tumor angiogenesis research development of anticoined the term 'tumor angiogenesis' (4) . The fundamental angiogenic drugs for cancer treatment. points of Folkman's visionary hypotheses can be summarized as follows: (i) most primary solid tumors probably go through 1. The discovery of basic fibroblast growth factor (bFGF) as a prolonged state of avascular, and apparently dormant, growth the first pro-angiogenic molecule Despite the logic of Folkman's ideas (1,2,7), sceptics awaited
Abbreviations: α-SMA, α-smooth muscle action; bFGF, basic fibroblast the precise identification of the hypothetical TAF molecule.
growth factor; TAF, tumor angiogenesis factor; VEGF, vascular endothelial growth factor.
This did not occur until the mid 1980s, when Shing et al. (13) reported that basic fibroblast growth factor (bFGF, also known stimulated intense interest in the biotech and pharmaceutical industries, as well as academic centres, using agents such as as FGF-2) isolated from a chondrosarcoma could function as a tumor-derived capillary growth factor and stimulate antibodies (28, [30] [31] [32] , VEGF-toxin conjugates (33) , aptamers (30) and small molecule VEGF receptor antagonists (34, 35) , angiogenesis in various models (14) . However, a puzzling feature about bFGF is that it lacks a signal sequence for among others. Another significant feature of VEGF is that levels of this secretion and generally remains intracellular, at least in cell culture. This cast some doubt on its authenticity as a major growth factor in tumor cells can be significantly enhanced by hypoxia (36). This can occur through both transcriptional and inducer of tumor angiogenesis (15). Nevertheless, the discovery provoked new interest in the field, and there is no doubt that post-transcriptional mechanisms, e.g. mRNA stabilization (37) . Given the impact of hypoxia as a mediator of tumor progression bFGF is recognized as a potent inducer of angiogenesis, including in the clinic for non-cancerous diseases such as hind (38) , and modulator of therapeutic responsiveness to agents such as radiation, the hypoxia/VEGF connection has heightened limb ischemia and ischemic heart disease (16-18).
awareness of angiogenesis among certain segments of the 2. The discovery of vascular endothelial growth factor (VEGF), cancer research and medical/radiation oncology communities. and VEGF receptor tyrosine kinases on activated endothelial cells 3 . The discovery of the angiopoietins and their tyrosine kinase receptors VEGF was initially termed vascular permeability factor (VPF), and still retains this term (15, 19) . Its first function (vascular A second family of ligands and receptors specific for vascular endothelial cells have been uncovered more recently (39) . In permeability) was discovered by Dvorak and colleagues (20, 21) and was first molecularly defined by Ferrara et al. (22, 23) . this case, it was the receptors that were discovered first, i.e. tie-2/tek and tie-1 (40, 41) . They remained as orphan receptors There are a number of families (VEGF, VEGF-B, VEGF-C, VEGF-D) of which VEGF (or VEGF-A as it is sometimes until 1996, when the ligands for one of them (tie-2), called angiopoietin-1 and angiopoietin-2 (ang-1 and ang-2), were called) is the most important; there are several VEGF isoforms and a number (e.g. VEGF 121 and VEGF 165 ) are readily secreted. discovered by Yancopolous and colleagues (42, 43) . Of considerable interest is the fact that although both ang-1 and ang-2 Moreover, unlike bFGF (as the name implies), VEGF is a very specific mitogen for vascular endothelial cells. It also functions bind tie-2, ang-1 functions as an agonist, whereas ang-2 behaves in a contrary manner (44) . Indeed, ang-2 can cause as a potent pro-survival (anti-apoptotic) factor for endothelial cells in newly formed vessels (24-26) and indeed this may be regression of newly formed vessels by endothelial cell apoptosis, unless VEGF is present, in which case the two one of its most significant functions. VEGF is expressed by the vast majority of cancers (20,21), often at elevated levels, collaborate to promote angiogenesis (45) . The ligand for tie-1 remains unknown. Similar to VEGF and its receptors, the and blocking its activity, e.g. by specific neutralizing antibodies to VEGF or to VEGF receptors expressed by 'activated' use of transgenic and gene knockout mice has been a powerful methodology to uncover the functional significance of the endothelial cells, can inhibit experimental tumor growth in vivo, but not in vitro (27, 28) . This is because of the highly elevated angiopoietin-angiopoietin receptor systems in both embryonic vasculogenesis and angiogenesis (46) . By way of example, and restricted expression of two receptor tyrosine kinases, called flk-1/KDR (also known as VEGF-receptor-2) and flt-1 embryonic mice which are only partially VEGF deficient, i.e. express one VEGF allele, do not survive in utero and express (also known as VEGF receptor-1), by the endothelial cells of newly formed blood vessels, which bind VEGF with high major defects in vasculogenesis and angiogenesis (46) . Mice made deficient in flk-1, flt-1 and tie-2 also do not survive in affinity (29) . Thus tumor cells can 'feed' (induce) new blood vessels by producing VEGF which, in turn, can nourish the utero (46) . In the case of flk-1-deficient mice, endothelial cells are not produced, whereas tie-2-deficient embryos produce tumor cells, an insidious and self-perpetuating paracrine loop. The possibility of therapeutic disruption of this loop has endothelial cells and form primitive vascular structures but these do not assemble into mature, stabilized vessels as a angiogenesis, such as VEGF (70,71), while other oncogenes, such as the erbB family, can stimulate VEGF production (67). result of a failure to recruit periendothelial support cells such Given the enormous interest in the molecular genetics of as pericytes and smooth muscle cells (46) . These developmental cancer, these relationships between cancer causing genetic biology and other gene knockout studies have been particularly changes and angiogenesis have fostered an increased awareness important contributions to the angiogenesis field in general, and of the importance of angiogenesis to the development, growth as such have had an accelerating effect on tumor angiogenesis and treatment of cancer. research as well. In particular, they have helped fuel interest in developing drugs which target VEGF, VEGF receptors, or 5. The discovery of additional molecular markers in newly the tie-2 receptors (35, 47) .
formed blood vessels, especially integrins and cell adhesion molecules
The discovery of endogenous inhibitors of angiogenesis
The discovery of VEGF receptors and their upregulation in Like the field of cancer genetics (48) , where virtually all the newly formed blood vessels highlights the fact that indeed, emphasis in the early years was placed on dominantly acting there can be major phenotypic differences between mature, oncogenes which act as positive acting stimulators of cell quiescent vessels, and their newly formed counterparts. Such growth, research in angiogenesis over the first 15-20 years differences are essential to avoiding unwanted toxicity to was also heavily focused on pro-angiogenic growth factor normal vessels when using anti-angiogenic drugs, and thus stimulators (14). Later, in the cancer genetics field, the concept achieving a sufficient therapeutic index. A number of such of (recessive) tumor suppressor genes came to be accepted, differences are now known, and include a very significant i.e. genes which encode proteins that normally function to elevation of expression in ECM-binding integrin receptors, block cell growth (or survival), and inactivation of which (e.g. such as α v β 3 or α v β 5 (72, 73) . This was first reported by by mutation or chromosome loss) can result in a loss of this Cheresh and colleagues (72) who exploited such differences cellular 'brake' mechanism (48) . It is now accepted that it is using specific neutralizing antibodies or small molecule peptide the combination of these two types of event which promote antagonists to block angiogenesis, which occurs, at least in cancer development and progression (48) . The same appears part, by induction of endothelial cell apoptosis. Other 'markers' to be the case for (tumor) angiogenesis (49) (50) (51) Table I) . Some of these are internal fragments of various 6. The development of quantitative assays for angiogenesis proteins which normally lack any anti-angiogenic activity
It is of course difficult to evaluate the function of angiogenic (51,65), e.g. angiostatin is one or more fragment(s) of plasmingrowth regulators in the absence of reliable assays. This was ogen (58) and endostatin is a fragment of type XVIII collagen a particularly serious problem in the early days of angiogenesis (59), as summarized in Table I . Many of the precursor proteins research since it had not been possible to successfully grow are components of the extracellular matrix (ECM)/basement vascular endothelial cells in long term culture until Folkman's membranes (e.g. type XVIII collagen and thrombospondin) or group established the appropriate conditions in 1980, and used members of the clotting/fibrinolytic pathways (e.g. plasminthem to elucidate the functional/sequential steps in angiogenesis ogen and anti-thrombin III) (64). (81) . Since then a number of semi-quantitative or quantitative It is now thought that the tumor angiogenic switch is assays have appeared that involve sprouting angiogenesis in triggered as a result of a shift in the balance of stimulators to tumor (cell) free systems (82) , such as the corneal micropocket inhibitors (50). When the ratio is low, tumor angiogenesis is assay, the subcutaneous 'Matrigel plug' assay (83) and assays blocked or modest in magnitude; in contrast, when the ratio involving growth of cut sections (slices) of blood vessels in is high, the switch is turned to the 'on' position (50). Of three dimensional gels of an ECM-associated material such as considerable interest was the finding by Bouck and colleagues, collagen (84) . The development of these systems has been a that loss of wild-type p53 gene function resulted in a loss of boost to the discovery of new stimulators and inhibitors of thrombospondin expression (52) . Not only did this finding angiogenesis, especially the latter (84). establish a possible critical link between the genetic basis of 7. Recognition of the prognostic significance of tumor cancer and tumor angiogenesis, it also opened up the now angiogenesis flourishing field of endogenous angiogenesis inhibitors. Furthermore, it is now increasingly recognized that oncogenes, Another major finding which attracted interest in the field was such as mutant ras, may also contribute to tumor angioreported by Weidner et al. (85) who found that the greater the genesis by influencing (i.e. enhancing) the production of prodegree of angiogenesis detected in a primary tumor, the worse angiogenic molecules such as VEGF (66-69). Such effects the prognosis. This established a direct relationship between were slow to be uncovered in the oncogene and tumor metastasis and angiogenesis. It was first shown in breast cancer suppressor gene fields given the predominant use of pure and subsequently a large and diverse array of other tumors, tumor cell culture systems to study the function of cancer including melanomas, gliomas, lung, bladder and prostate causing genetic alterations.
cancers, and many others (86). Tumor vascularity is measured Other tumor suppressor genes, in their non-mutant, wildby staining tissue sections with antibodies specific (or highly type form, such as VHL (von Hippel-Lindeau) and p16, specific) for antigens expressed by vascular endothelial cells such as factor VIII (von Willibrand factor), CD-31 or CD-34 have been shown to block the production of regulators of (86) and then counting (under high power) the number of venting acquired drug resistance came from long term, cyclic exposure of tumor-bearing mice with the anti-angiogenic highlighted vessels in so-called vascular 'hotspots' i.e. localized protein drug known as endostatin (91) . Unlike conventional areas where there are unusually high numbers of vessels, as cyclophosphamide therapy, using maximum tolerated doses detected first under lower power magnification (85) . administered in an intermittent fashion, no resistance to endoAside from the prognostic implications of this work, it also statin was ever seen and the tumors eventually stopped growing served to highlight the extent to which tumor masses can after a certain number of cycles of therapy (91) . This work become 'contaminated' by blood vessels. Many such vessels probably attracted more attention than perhaps any other single are very small and deformed, containing bizarre tortuosities, study on tumor angiogenesis, if not cancer research, over the corkscrew structures, blind ends and abnormal branching last decade (92, 93) . characteristics, thus making many of them almost impossible Given the great importance (and effort) attached to developto detect in a normal hematoxylin and eosin tissue section.
ing drugs, or therapeutic strategies, to reverse (or actually Consequently, the degree of tumor angiogenesis had been prevent) acquired drug resistance, e.g. the use of P-glycoprotein underestimated, and hence less appreciated, prior to publication antagonists such as cyclosporin analogues to block multidrug of this type of work. In this regard, endothelial cells are a rich resistance and the fact that such efforts have not met with source of biologically active substances such as cytokines and much clinical success, at least thus far (94) (95) (96) , the results proteases (87, 88) which can themselves affect the behavior of obtained using endostatin have certainly increased interest in adjacent cancer cells independent of classic angiogenesis, i.e. the pharmaceutical industry for using this type of therapeutic of providing oxygen and nutrients.
approach as a means of treating cancer. Indeed, it is also Detection of blood vessels in tissue sections has recently possible to use conventional cytotoxic drugs as potent directbeen modified by Benjamin et al., so that it is now possible acting 'resistance-free' cytotoxic anti-endothelial agents by to discriminate between newly formed immature vessels and such methods as peptide-based targeting strategies (97) or those that are more established and mature (26). It is based altering the dosing and schedules of the drug so as to create on the use of antibodies to α-smooth muscle action (α-SMA), an 'anti-angiogenic' schedule of chemotherapy (98,99). which appears to stain the latter type of vessel as a result of Nevertheless, it should be noted that some anti-angiogenic mature vessels attracting a 'coat' of periendothelial support drugs work by blocking a particular redundant tumor cell cells, i.e. pericytes and smooth muscle (α-SMA-antigen-posiproperty, such as VEGF production, and thus may be subject tive) cells (26). Of interest is the finding that anti-angiogenic to inactivation over time by classic acquired resistance mechantherapeutic procedures, such as blockade of tumor cell VEGF isms since, for example, tumor cells can produce a number of production, results not only in a drop in the vessel count, but different pro-angiogenic growth factors. Therefore, rare cellular also a change in the ratio of immature/mature vessels because variants producing a spectrum of different pro-angiogenic of the relative vulnerability of the immature vessels to this, molecules will likely be selected by the therapy. This could and most other, forms of anti-angiogenic therapy.
be an important factor in determining the best anti-angiogenic 8. Lack of acquired resistance to direct-acting anti-angiodrugs to use, given that treatments using such drugs are genic drugs probably going to be chronic in nature. In other words, it may It was first proposed in 1991 by Kerbel (89) that antibe useful to think in terms of 'direct-acting' anti-angiogenic agents, such as endostatin, and those that are 'indirect acting', angiogenic therapy might bypass a major problem encountered such as a drug that blocks a pro-angiogenic growth factor in virtually all strategies used to treat cancer, especially produced by tumor cells, or even its relevant endothelial cell chemotherapy and hormonal ablation/antagonist therapies, receptor tyrosine kinase (90). An indirect acting anti-angiogenic namely acquired drug resistance. The underlying rationale was agent, such as an anti-VEGF neutralizing antibody, could be that the cellular target of anti-angiogenic drugs is a normal, converted to a direct-acting agent by such procedures as and hence genetically stable, host cell, i.e. the vascular endoconjugating the antibody with a toxic radionuclide or a toxin thelial cells which line newly formed blood vessels in tumors.
molecule such that binding of the antibody to endothelial cells Because acquired resistance is largely a consequence of the results in direct endothelial cell death. In addition, there are small and large scale genetic instabilities associated with cancer reports showing that the majority of the VEGF produced in a cells (e.g. gene amplification, chromosomal translocations, tumor mass appears to come from the normal host stromal chromosome loss, simple point mutations, etc.), it should cells infiltrating the tumor, rather than the tumor cell population not develop when using certain anti-angiogenic therapeutic itself (100). Use of VEGF blocking antibodies in such situations strategies (89), just as heritable, and acquired resistance does may not be compromised by the rapid development of acquired not emerge among the descendants of drug-sensitive normal drug resistance (90). host cells exposed to chemotherapy, e.g. dividing bone marrow, Finally, with respect to the issue of drug resistance, antigut mucosal or hair follicle cells (90). Clinical 'experiments angiogenic therapies may also circumvent what may be a of nature' provided the first indication that, indeed, acquired major mechanism of intrinsic drug resistance, namely insuffiresistance may not be inevitable when using certain anticient drug penetration into the interior of a tumor mass due to angiogenic drugs. Thus, long term (eg. 1 year), daily treatment high interstitial pressure gradients within tumors (101). Target-(using interferon α2β) of infants with life-threatening hemangiing the tumor vasculature (rather than the tumor cell population) omas can result in complete regression of these benign blood would avoid the necessity of having to obtain intra-tumor drug vessel tumors without any evidence of the development of delivery (101) . acquired resistance to this drug (56). In contrast, chronic 9. The discovery of the impact of angiogenesis on 'liquid' exposure of malignant cancer cells to the same type of drug hematologic malignancies is known to result in acquired interferon resistance among variants of the treated cancer cells (54) Another remarkable recent development, and one that is clearly counter-intuitive as well, is the recent realization that so-called The first preclinical/experimental evidence for circum-'liquid' hematologic malignancies are angiogenesis dependent results in a secondary, but much more massive, wave of (102-104), i.e. this is not just a property of solid tumors. The apoptotic cell death in the cords of tumor cells surrounding discovery was based on findings such as elevated levels of the regressive/dying vessels (113) . This secondary cell death pro-angiogenic growth factors, i.e. bFGF and VEGF, in the process leads to the regression of tumor mass (113) . Unfortuserum and urine of patients with acute lymphatic leukemia nately such tumors will eventually recur due to the emergence and multiple myeloma (102). Similarly, a sharp increase in of hormone refractory tumor cell variants (113) . Thus, this bone marrow angiogenesis, as measured by means of vessel would be another example of an indirect acting anti-angiogenic density in vascular hot spots, has also been detected in such therapy, or drug, to which resistance may develop. patients (102). The newly formed blood vessels detected in
In addition to conventional therapeutic agents, some of the the marrow of patients with acute lymphoytic leukemia or newer generation of anti-cancer drugs making their way into multiple myeloma could be a rich source of growth factors the clinic (and which were never designed with the intent of and cytokines, as well as survival factors, for tumor cells that inhibiting angiogenesis) may affect tumor growth, partly by arise in this tissue.
suppression of tumor angiogenesis. An example is the soThis work has already resulted in the initiation of early called signal transduction inhibitor therapies which target the phase I clinical trials to test putative anti-angiogenic drugs products of mutant oncogenes, such as ras, or overexpressed such as thalidomide (105) in multiple myeloma patients, the proto-oncogenes such as the EGF receptor tyrosine kinase and results of which look very encouraging (106). If this holds up the erbB2/Her-2 receptor tyrosine kinase (69). The drugs in and is found to be a consequence of an anti-angiogenic effect question include small molecule inhibitors of mutant ras (or it would provide major impetus to a large segment of the a related target) such as ras farnesyltransferase inhibitors (Ras medical oncology community to become much more actively FTIs) and monoclonal neutralizing antibodies to the EGF engaged in angiogenesis research and anti-angiogenic therapies receptor, such as C225, or to erbB2/Her2, e.g. Herceptin (69). to treat these types of cancer.
Their potential ability to block angiogenesis (69) 
. Thus, treatment using drugs which block oncoprotein A number of discoveries led to the provocative conclusion that the use of anti-angiogenic drugs and therapies-in the function may result in downregulation of VEGF, and perhaps clinic-is, in reality, probably not a new development. Oncoloother pro-angiogenic growth factors (66,67). This could congists may have been using them without realizing it for tribute to the drug's overall therapeutic effect in vivo, where decades, albeit in a less than optimal manner. This is based angiogenesis is required, but not in vitro, where angiogenesis on preclinical data showing that various cytotoxic drugs such is irrelevant for tumor cell growth and survival, a possibility as taxanes (107-109), topoisomerase inhibitors (110), purine which could help explain why such drugs may lack cytotoxic analogue anti-metabolites (111), radiation therapy (112) and properties in vitro but sometimes express such an effect in vivo hormonal ablation therapeutic procedures (26,113,114) can all (69). Similar reasoning is evident with a number of other result in either direct or indirect killing of vascular endothelial drugs and therapeutic modalities such as interleukin-12 based cells of newly formed tumor blood vessels. Denekamp and immunotherapy (121). colleagues were the first to have the insight to point out these Finally, with respect to the effects of traditional/conventional 'accidental' anti-vascular effects using various rodent tumor therapeutics, mention should be made of the findings of Teicher models and a diverse spectrum of anti-cancer agents ranging and colleagues, where it has been shown preclinically that the from cytokines/biological response modifiers and ionizing combination of an anti-angiogenic drug (or drugs) (such radiation to chemotherapeutic drugs and photodynamic therapy as TNP-470) with a conventional cytotoxic agent, such as (115). Denekamp coined the term 'vascular targeting' to cisplatinum, taxol or cyclophosphamide, can significantly describe this effect (115). The possibility of optimizing the improve the anti-tumor efficacy of the cytotoxic drug (122).
anti-vascular targeting effects of chemotherapeutic drugs by
This observation is counterintuitive since it might be expected altering the drug doses and schedules used for therapy has that anti-angiogenic agents would decrease blood flow into been elegantly shown by Folkman and colleagues (98), as well tumors and, hence, limit drug delivery to tumors. However, as Klement et al. (99) .
just the opposite may be the case (123) , and this may be due More recently, much interest has been aroused by findings to a transient normalization of the abnormal structure of which relate to how withdrawal of androgens may cause tumor vessels mediated by certain angiogenesis inhibitors, e.g. regression of hormone-sensitive cancers, such as prostate neutralizing anti-VEGF antibodies (124) , thus leading to the cancer, at least in part through an anti-angiogenic mechanism possibility of a temporary increase in blood flow and, hence, (26,113). The basis for this intriguing possibility is that drug delivery (123) . Alternatively, there is the potential for a androgens are powerful inducers of VEGF in hormone-sensitive cytotoxic drug to function directly on endothelial cells of tissues (114) and VEGF, in turn, is a potent powerful survival newly formed tumor vessels; this effect may be exaggerated by factor for endothelial cells of newly formed immature blood the inclusion of an anti-angiogenesis drug which compromises vessels (24), perhaps by upregulating bcl-2 (116,117) or endothelial cell survival mechanisms (99) . Regardless of the activating the PI3 kinase/Akt/PKB survival/signalling pathway actual mechanism, these combination therapy effects, which (118,119) in endothelial cells. Hence, acute withdrawal of have also been observed with radiation therapy and angiogentumor cell VEGF, which could occur in patients or animals esis inhibitors (112), could play a significant role in the with androgen-dependent tumors after androgen ablation therclinical evaluation and effects of angiogenesis inhibitors, as apy, can result in rapid apoptosis of the endothelial cells comprising such immature tumor vessels (113) . This, in turn, discussed below. The future: opportunities to be seized, problems to in combination with an angiogenesis inhibitor. Clearly, the success of Herceptin in improving the effects of cytotoxic overcome chemotherapy in a proportion of advanced-stage breast cancer Figure 1 , which shows various anti-angiogenic drugs currently patients has given this strategy of evaluating cytostatic drugs in clinical development, highlights the obvious fact that we much added credibility (131) . This could allow conventional shall soon have some kind of indication of the potential value endpoints such as tumor shrinkage and prolongation of survival of this kind of new therapeutic approach to treat cancer. While of very sick patients to be used, albeit indirectly, as a this is an exciting time, there are a number of problems which convenient means of more rapidly assessing the merit of anticould hamper progress in the field and overall enthusiasm for angiogenic drugs. the concept of anti-angiogenic therapy. Tackling these problems
Another possible resolution to this problem could come presents some challenging opportunities; success in doing so with the increased use of improved 'anti-vascular targeting' would help foster a new era of cancer therapeutics in the clinic. strategies which can cause acute tumor regressions, as shown Some of the problems and opportunities are discussed below.
in various preclinical models. For example, certain tubulinThe difficulties associated with clinical evaluation of antibinding agents (109) such as combretastin A-4 can cause such angiogenic drug efficacy an effect (125, 132, 133) as can antibodies which target tissue The nature of most anti-angiogenic drugs makes it difficult to factor to newly formed blood vessels, thus causing an intravasevaluate their potential efficacy in early phase clinical trials cular thrombogenic response in such vessels (134) . These since, with few known exceptions (91, (126) (127) (128) , they do not drugs kill endothelial cells of newly formed blood vessels by cause overt or rapid tumor regression, as can conventional different mechanisms (133), thus causing a vascular collapse cytotoxic agents (129) . Thus, obvious tumor shrinkage and the subsequent death of much larger numbers of tumor observed over a relatively short period of time is unlikely to cells. Clearly the problem here will be to develop drugs which be encountered. Indeed, if one uses the example of chronic have this ability to cause such a dramatic 'tumor infarction' interferon α2β administration of either life-threatening heman-(134) without major, perhaps even life-threatening, toxic side giomas (56) or giant cell tumors of the mandible (130), the effects. In this regard, a potentially significant development in effects of the therapy are not initially detected for several the near future could be the use of genomics based technologies months, which is then followed only by a very gradual to uncover a large number of highly (or even totally) specific regression of these benign tumors. This necessitates a molecular markers for the activated endothelial cells of newly reappraisal of the design and needs of early phase clinical formed blood vessels. This could make antibody based theratrials to test such agents in a number of ways (127, 129) . For peutics safer and more effective. example, it will probably result in increased emphasis on What will also be required are vastly improved means to combining anti-angiogenic agents with conventional cytotoxic definitively show that a cytostatic anti-angiogenic agent has drugs since, as discussed above, preclinical evidence suggests the desired biological (i.e. anti-angiogenic) effect in vivo, in that the efficacy of a conventional cytotoxic drug can be the absence of acute tumor regression, when the agent is improved by combination with an angiogenesis inhibitor (122) .
cytostatic and is tested in the absence of a chemotherapeutic Indeed, a number of anti-angiogenic clinical trials currently in drug. This is difficult, to say the least, even in experimental progress have been designed to compare the effects of a animal models, let alone patients. In the experimental animal situation, tumors can be removed and examined for such particular cytotoxic agent alone compared with this same agent changes as the extent of vascularization, vascular structure, such sites as the lungs, liver, brain and bone, especially since it cannot be assumed that an angiogenesis inhibitor that is endothelial cell viability or apoptosis, as well as for markers of angiogenic activity, e.g. VEGF expression. Taking serial effective in the particular organ site, e.g. the lungs, will be equally effective in other sites. For example, there appear to biopsies of metastatic tumors may not be a particularly practical or desirable approach in the clinical situation. As such, reliable be organ-specific endothelial markers and the vasculature of a tumor mass can differ depending on the site of growth surrogate markers of tumor angiogenesis found in serum or urine may be necessary. At present few, if any (at least of a (97, 131, (142) (143) (144) . Hence some anti-angiogenic drugs, depending on their target, may show large differences in antireliable nature), such markers exist. The use of various non-invasive medical imaging strategies (e.g. MRI, doppler tumor efficacy as a function of organ site (145) . In this regard, new and improved metastasis models are being developed, ultrasound) to monitor changes in tumor blood flow, vascular structure and permeability may be the most fruitful approach such as the use of firefly luciferase on green fluorescent protein-tagged tumor cell lines which greatly enhance detection and, indeed, there are considerable research efforts (and some successes) underway in this area (135) (136) (137) (138) (139) .
of microscopic and macroscopic metastases in many different organ sites (146,147). In addition, the use of orthotopically The prospect of delayed toxicity associated with long-term transplanted tumors may be preferable for these studies, not anti-angiogenic therapy only to induce or enhance the incidence of metastases but also Another obvious problem is that toxic effects associated with because the response of a tumor mass growing ectopically chronic anti-angiogenic therapy may not show up in short (e.g. a colon tumor transplanted into the subcutaneous space) term early phase clinical trials or animal models, but rather, may be abnormal compared with the same tumor growing in only after very protracted courses of therapy using these new a physiologically relevant site (147-150). drugs. The development of spastic diplegia in some infants or
Another problem associated with the use of such rapidly children who had been treated previously and successfully growing transplantable tumor models is that, by definition, over 1 year with anti-angiogenic (interferon α2β) therapy for they will contain an extremely high proportion of newly their life threatening hemangiomas (140) is an example of formed immature vessels, and it is just such vessels which such delayed toxic side effects. This undoubtedly will increase appear to be especially vulnerable to the effects of most antithe need for very highly specific or completely specific targets angiogenic drugs (26). Presumably, spontaneous, slow-growing expressed by blood vessels on tumors. The growing intertumors in humans, which may have been incubating for years relationship between the clotting and fibrinolytic pathways, and before their detection, would have a much lower proportion angiogenesis (64) raises the possibility of bleeding/coagulation of immature vessels, and thus would be much less responsive disorders in patients who receive certain anti-angiogenic drugs, to most forms of anti-angiogenic therapy. Consequently, the as well as causing or exacerbating existing cardiovascular use of spontaneous tumors in rodents should probably be used defects in older patients. Such problems may not show up in in conjunction with the more traditional transplantable tumor short-term preclinical studies utilizing mice which are Ͻ2 or models, when testing anti-angiogenic drugs, as shown by 3 months of age (the standard practice) as opposed to much several groups such as Hanahan and colleagues (151,152) and older mice. In addition, there is the obvious concern about Dexter et al. (153) using various transgenic 'oncomouse' affecting physiologic forms of angiogenesis in various situmodels. Such mice are harder to work with in many ways, ations. Thus, wound healing may be adversely affected in a and clearly less economical (154) but the results obtained cancer patient who is receiving anti-angiogenic drugs, as would using such models may ultimately provide a more faithful 'reproductive angiogenesis', e.g. corpus luteum development picture of what will occur later in the clinic (153) , although in adult females, and development of the vasculature in this has yet to be proved. developing embryos. Growth in neonates may also be com-A final point worth raising concerns the relative proportions promised by angiogenesis inhibitor therapies (141) . However, of 'new' (immature) vessels versus 'older' mature vessels in given the unique structural features of the tumor vasculature, tumors, and stems from the recent work of Benjamin et al. some angiogenesis inhibitors may selectively block tumor (26) and Holash et al. (45) . The latter group has reported that angiogenesis without actually affecting other physiological tumor cells may actually parasitize ('co-opt') pre-existing host forms of angiogenesis. This possibility could turn out to be organ blood vessels in sites of metastases or in vascularized an important factor in selecting the optimal angiogenesis organs such as the brain in order to initiate blood-vesselinhibitors for clinical development and their use in cancer dependent tumor growth (45) as opposed to classical angiogenpatients.
esis mechanisms. These co-opted vessels then actually regress The need for better animal tumor/therapy models as a result of induction of apoptosis of the constituent endothelial cells, a process apparently mediated by angiopoietin-2 (45). Most preclinical studies on tumor angiogenesis and antiangiogenic therapy usually employ rapidly growing transplantSubsequently, this is followed by induction of angiogenesis at the periphery of the growing tumor mass by a co-operative able mouse tumors, or human tumor xenografts, which are usually grown as a solid, localized tumor in the subcutaneous interaction of VEGF and angiopoietin-2 (45). Thus, there may be a dynamic equilibrium established between regression of space. For several reasons this approach almost certainly exaggerates the anti-tumor responses observed using anti-'established' vessels and the formation of new ones, a process which may favour a relatively constant and very high ratio of angiogenic drugs, as well as other types of anti-tumor agents. First, in such experimental situations, unlike the clinic, distant immature to mature vessels in spontaneous human tumors. In this respect it is interesting to note that Bejnamin, Keshet and visceral metastases are usually not the focus of the treatment, and it is precisely such secondary tumors (which are often colleagues analyzed highly malignant human glioblastomas obtained from patients using antibodies to α-SMA to distinmuch harder to treat) which are ultimately responsible for cancer's lethality. Hence, more emphasis should be placed upon guish between mature (α-SMA-positive) and immature (α-SMA-negative) vessels (26), and found very high (e.g. Ͼ80%) evaluating anti-angiogenic therapies on metastases growing in 
